Abstract

Research Article

Budesonide – Oral Galenic Formulations for Crohn Disease

Luisetto M, Mashori GR, Cabianca L and Latyshev OYU

Published: 11 October, 2024 | Volume 8 - Issue 1 | Pages: 028-033

The aim of this work is to verify the pharmaceutical form in the galenic field of oral Budesonide compounded used in Crohn’s disease: capsules delay release or oral suspension. In particular ways the kinds of excipients or bases-vehicle used in the galenic pharmacy practice. The therapeutic need for Crohn’s disease requires a release of the API in delayed-release DR. The Budesonide molecule shows low systemic impacts due to its hepatic metabolism vs. a topical effect useful in this pathology. In this work, the oral pharmaceutical forms are analyzed: modified-release capsules and oral suspension with specific advantages for each one. Some formulations provided by various pharmacies are reported in this work as well as new technology like the 3D-PRINTING systems for colonic targeting tablets.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001048 Cite this Article Read Full Article PDF

Keywords:

Budesonide; Crohn's disease; Pediatric; Delay release; Capsules acid resistance filled with HPMC; Metolose; Methocel; Oral suspension; Ready for use vehicle; 3D printing

References

  1. Kelsen J, Baldassano R N. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008;14(suppl_2):S9-11. Available from: https://doi.org/10.1002/ibd.20560
  2. Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088-1103. Available from: https://doi.org/10.1016/j.mayocp.2017.04.010
  3. Brandi Jones M-E, Rekhi S. What’s the difference between Crohn’s disease and ulcerative colitis? Health. 2024 Feb 7. Available from: https://www.health.com/crohns-disease-vs-ulcerative-colitis-8405457
  4. Crohn’s Disease. Johns Hopkins Medicine. 2022 Apr 19. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/crohns-disease
  5. von Allmen D. Pediatric Crohn's disease. Pediatr Congenit Colorectal Dis Adult Patient. 2018;31(2):80-88. Available from: https://doi.org/10.1055/s-0037-1609022
  6. Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Ther Adv Gastroenterol. 2022;15:17562848221078456. Available from: https://doi.org/10.1177/17562848221078456
  7. Greenberg G R, Feagan B G, Martin F, Sutherland L R, Thomson A, Williams C N, et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994;331(13):836-841. Available from: https://doi.org/10.1056/nejm199409293311303
  8. Budesonide 2 mg/10 ml Oral Suspension | Formulas | Bayview Pharmacy. Available from: https://www.bayviewrx.com/formulas/Budesonide-2-mg-10-ml-Oral-Suspension-Asthma-Allergic-Rhinitis-Crohn-s-Disease-Ulcerative-Colitis-Eosinophilic-Esophagitis
  9. Budesonide (oral route). Mayo Clinic. 2024 Oct 1. Available from: https://www.mayoclinic.org/drugs-supplements/budesonide-oral-route/description/drg-20073233
  10. Budesonide Te Arai. Budesonide Te Arai Data Sheet v 3.0 July 2023. Available from: https://www.medsafe.govt.nz/profs/datasheet/b/BudesonideTeAraicap.pdf
  11. Hennig M, Hennig M. Colon-targeted delivery systems of budesonide as second-line therapy in inflammatory bowel disease. Pharma Excipients. 2024 Feb 25. Available from: https://www.pharmaexcipients.com/news/budesonide-second-line/
  12. O'Donnell S, O'Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177-186. Available from: https://doi.org/10.1177/2040622310379293
  13. Budesonide 10 mg Slow Release Acid Resistant Capsules | Formulas | Bayview Pharmacy. Available from: https://www.bayviewrx.com/formulas/Budesonide-10-mg-Slow-Release-Acid-Resistant-Capsules-Asthma-Crohn-s-Disease-Ulcerative-Colitis-Allergic-Rhinitis-Eosinophilic-Esophagitis
  14. Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th ed. Pharmaceutical Press; 2006;918. https://books.google.co.in/books/about/Handbook_of_Pharmaceutical_Excipients.html?id=BGJqAAAAMAAJ
  15. Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, et al. Efficacy and safety of oral budesonide in patients with active Crohn's disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study. Inflamm Intest Dis. 2018;2(3):154-162. Available from: https://doi.org/10.1159/000484047
  16. Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12(1):29-32. Available from: https://doi.org/10.1097/01.mib.0000192323.82426.83
  17. Ou YH, Goh WJ, Lim SH. Form & formulation approaches for COntRollable Release in 3D printed Colonic Targeting (CORR3CT) budesonide tablet. Int J Pharm. 2023;635:122680. Available from: https://doi.org/10.1016/j.ijpharm.2023.122680
  18. Cortesi R, Ravani L, Menegatti E, Esposito E, Ronconi F. Eudragit® microparticles for the release of budesonide: a comparative study. Indian J Pharm Sci. 2012;74(5):415-421. Available from: https://doi.org/10.4103/0250-474x.108416
  19. Iborra M, Álvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol. 2014;39-46. Available from: https://doi.org/10.2147/ceg.s34715
  20. Dressman J. Comparative dissolution of Budesonide from four commercially available products for oral administration: implications for interchangeability. Dissol Technol. 2023;30:224-229. Available from: https://dissolutiontech.com/issues/202311/DT202311_A02.pdf
  21. MMXTM technology and its applications in gastrointestinal diseases - Tasnim Pharmaceutical Company. Tasnim Pharmaceutical Company. 2023 Jul 19. Available from: https://tasnimpharma.com/mmx-technology/
  22. Moghrabi FS, Fadda HM. Drug physicochemical properties and capsule fill determine extent of premature gastric release from enteric capsules. Pharmaceutics. 2022;14(11):2505. Available from: https://doi.org/10.3390/pharmaceutics14112505
  23. Shin-Etsu technical information - SE Tylose. Extended Release of Vitamin C Matrix Tablets with TYLOPUR Xtend Nutra®. Available from: https://www.setylose.com/en/knowledge-base/healthcare/technical-information#tylopur-xtend-nutra-10231

Figures:

Similar Articles

  • Treatment of perianal fistulae in crohn's disease with mesenchymal stem cells
    Mohamed Hassin Mohamed Chairi*, Francisco José Huertas Peña, Marta Santidrián Zurbano, Tomás Torres Alcalá and Jesús María Villar del Moral Mohamed Hassin Mohamed Chairi*,Francisco José Huertas Peña,Marta Santidrián Zurbano,Tomás Torres Alcalá,Jesús María Villar del Moral. Treatment of perianal fistulae in crohn's disease with mesenchymal stem cells. . 2022 doi: 10.29328/journal.acgh.1001033; 6: 006-020
  • Budesonide – Oral Galenic Formulations for Crohn Disease
    Luisetto M, Mashori GR, Cabianca L and Latyshev OYU Luisetto M, Mashori GR, Cabianca L, Latyshev OYU. Budesonide – Oral Galenic Formulations for Crohn Disease. . 2024 doi: 10.29328/journal.acgh.1001048; 8: 028-033

Recently Viewed

  • Pattern of Eye Disease in Nenwe Rural Eye Clinic, Nigeria: A Seven Year Review
    Nnenna Maureen Ozioko*, Nkiru Mary Okoloagu, Emmanuel Sunday Onah and Catherine Nnenna Maureen Ozioko*, Nkiru Mary Okoloagu, Emmanuel Sunday Onah, Catherine. Pattern of Eye Disease in Nenwe Rural Eye Clinic, Nigeria: A Seven Year Review. Int J Clin Exp Ophthalmol. 2024: doi: 10.29328/journal.ijceo.1001056; 8: 004-015
  • Retinopathy of prematurity - Intersibling divergence of risk factors among twins
    Sudeep Navule Siddappa*, Kavitha Chikknayakanahalli Venugopal, Pavana Acharya and Tintu Susan Joy Sudeep Navule Siddappa*,Kavitha Chikknayakanahalli Venugopal,Pavana Acharya ,Tintu Susan Joy . Retinopathy of prematurity - Intersibling divergence of risk factors among twins. Int J Clin Exp Ophthalmol. 2020: doi: 10.29328/journal.ijceo.1001026; 4: 009-011
  • Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency
    Dabholkar Yogesh, Shah Tanush, Rathod Roheet, Paspulate Akhila, Veligandla Krishna Chaitanya, Rathod Rahul, Devesh Kumar Joshi* and Kotak Bhavesh Dabholkar Yogesh, Shah Tanush, Rathod Roheet, Paspulate Akhila, Veligandla Krishna Chaitanya, Rathod Rahul, Devesh Kumar Joshi*, Kotak Bhavesh. Effectiveness of levocetirizine in treating allergic rhinitis while retaining work efficiency. Arch Asthma Allergy Immunol. 2023: doi: 10.29328/journal.aaai.1001031; 7: 005-011
  • Hepatic Pseudolymphoma Mimicking Neoplasia in Primary Biliary Cholangitis: A Case Report
    Jeremy Hassoun, Aurélie Bornand, Alexis Ricoeur, Giulia Magini, Nicolas Goossens and Laurent Spahr* Jeremy Hassoun,Aurélie Bornand,Alexis Ricoeur,Giulia Magini,Nicolas Goossens,Laurent Spahr*. Hepatic Pseudolymphoma Mimicking Neoplasia in Primary Biliary Cholangitis: A Case Report. Arch Case Rep. 2024: doi: 10.29328/journal.acr.1001115; 8: 152-155
  • Other Applications of Amniotic Membranes: Case Series
    Linda Guerrero* Linda Guerrero*. Other Applications of Amniotic Membranes: Case Series. Arch Case Rep. 2024: doi: 10.29328/journal.acr.1001117; 8: 159-162

Read More

Most Viewed

Read More

Help ?